Future therapeutic targets in rheumatoid arthritis?

Tommy Tsang Cheung1 · Iain B. McInnes2

Received: 16 March 2017/Accepted: 29 March 2017/Published online: 27 April 2017
© The Author(s) 2017. This article is an open access publication

Abstract Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with RA will develop joint deformity and progressive functional impairment. With the implementation of treat-to-target strategies and availability of biologic therapies, the outcomes for patients with RA have significantly improved. However, the unmet need in the treatment of RA remains high as some patients do not respond sufficiently to the currently available agents, remission is not always achieved and refractory disease is not uncommon. With better understanding of the pathophysiology of RA, new therapeutic approaches are emerging. Apart from more selective Janus kinase inhibition, there is a great interest in the granulocyte macrophage-colony stimulating factor pathway, Bruton’s tyrosine kinase pathway, phosphoinositide-3-kinase pathway, neural stimulation and dendritic cell-based therapeutics. In this review, we will discuss the therapeutic potential of these novel approaches.

Keywords Rheumatoid arthritis · GM-CSF · JAK · BTK · PI3K · Tolerogenic dendritic cells

Introduction Rheumatoid arthritis is a chronic inflammatory disease characterized by persistent joint inflammation. Without adequate treatment, patients with rheumatoid arthritis (RA) will develop joint deformity and progressive functional impairment. Substantial evidence indicates that persistent systemic inflammation and immune dysfunction plays a major role in the development of co-morbidities, such as cardiovascular diseases, osteoporosis, interstitial lung disease and malignancies. Large retrospective cohorts have shown that the risk of myocardial infarction is at least 1.5 times higher compared with controls [1, 2] and patients with RA have increased cardiovascular mortality as a result [3–5]. In addition, many studies consistently indicate an increase in the incidence of malignancies, such as lymphoma [6–8]. As a result, patients with RA have reduced quality of life and life expectancy.

With the implementation of treat-to-target strategies, the outcomes of patients with RA have significantly improved. The likelihoods of achieving remission and low disease activity are significantly higher compared with usual care and historical controls. As a result, those patients experience less functional impairment [9–15]. Strategic approaches of this nature not only alleviate clinical symptoms of RA but also demonstrate significant benefits to RA-associated co-morbidities. Osteoporosis is significantly less frequent in patients with disease remission, and a similar trend was also observed for cardiovascular disease [16]. Patients in remission have a significant reduction in cardiovascular risk that is comparable to that of healthy controls [17].

In parallel, biologic therapies have revolutionized the treatment paradigm of RA because they are generally more effective than conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). Even biologic therapies currently available only demonstrate clinical efficacy in about two thirds of patients. As a result, the unmet need in the treatment
of RA remains high, remission rates are insufficient and new therapeutic approaches should be explored especially for those patients with refractory disease. In this review, we will discuss the potentials of several novel therapeutic agents.

**Extracellular target in RA**

A range of extracellular targets are currently under consideration. The majority concern previously targeted cytokines, e.g. IL-6R or ligands, IL-6. Recent studies targeting a variety of cytokines, e.g. IL-17, IL-20 and IL-21, have been disappointing [18–24]. Herein, we will focus on one novel cytokine that has elicited promising data in early trials.

**Granulocyte macrophage-colony stimulating factor**

Granulocyte macrophage-colony stimulating factor (GM-CSF) is a haematopoietic growth factor responsible for the differentiation and proliferation of myeloid cells, including neutrophils, dendritic cells and macrophages. In addition, GM-CSF also induces migration and proliferation of endothelial cells [25]. It is produced by a wide variety of cell types, such as myeloid cells, lymphocytes and tissue-resident cells including chondrocytes, fibroblasts, osteoblast and endothelial cells [26, 27]. Production of GM-CSF can be stimulated by multiple agents, such as lipopolysaccharide, tumour necrosis factor, IL-1 and IL-23 [28]. It binds to a heterodimeric GM-CSF receptor, which consists of a ligand-specific binding α-chain and a signal transducing β-chain [29]. Subsequent signalling from the GM-CSF receptor activates Janus kinase-signal transducer and activator of transcription (JAK-STAT), phosphoinositide-3-kinase (PI3K) and MAPK pathway [30, 31].

GM-CSF plays a crucial role in innate immune responses. In general, it enhances the effector functions of neutrophils and macrophages, leading to increased expression of adhesion molecules, production of inflammatory cytokines and activation of phagocytosis [32]. GM-CSF can also polarize macrophages into an inflammatory M1 phenotype, which are involved in synovial inflammation [33]. GM-CSF is also involved in the development, maturation, antigen presentation and cytokine production by dendritic cells [34–36]. Several in vitro studies show that GM-CSF stimulates the development of inflammatory dendritic cells. These inflammatory dendritic cells produce pro-inflammatory cytokines, such as TNF, IL-12 and IL-23. Following antigen engagement and conditioning by the pro-inflammatory cytokines, the inflammatory dendritic cells are able to present self-antigens and stimulate T cell in the lymph nodes [37, 38].

In patients with RA, GM-CSF is expressed in the synovial membrane and the level of GM-CSF is increased in the synovial fluid [39]. Increased expression of GM-CSF receptors is found on circulating monocytes [40], which promotes the subsequent maturation and activation of macrophages in the synovium. In addition, GM-CSF receptors are up-regulated in the synovial tissue [41], and in vitro studies show that GM-CSF induces the proliferation of fibroblast-like synoviocytes [42]. GM-CSF also contributes to the differentiation and survival of Th17 cells and dendritic cells [43]. In the presence of GM-CSF, monocyte-derived dendritic cells maintain their inflammatory potential and are resistant to the immunosuppressive effect of IL-10 in vitro [44]. These dendritic cells also produce high levels of IL-1, IL-6 and TNF-α [45] and are able to present auto-antigens via MHC molecules, contributing to the pathogenesis of RA [46].

Based on these findings, GM-CSF inhibition is an attractive therapeutic target for RA. In animal models, administration of GM-CSF exacerbates arthritis in the collagen-induced arthritis (CIA) model, while administration of neutralizing antibodies against GM-CSF prevents disease progression [47, 48]. In view of the robust effects of GM-CSF inhibition demonstrated in pre-clinical studies, the efficacy of GM-CSF inhibitors has been evaluated in clinical trials [49].

Mavrilimumab is a monoclonal antibody against the human GM-CSF receptor alpha chain. In the EARTH EXPLORER I study, 326 patients with active RA and who had previously an inadequate response to DMARDs were randomized to receive different doses of mavrilimumab versus placebo. In this phase IIb study, a greater proportion of patients receiving mavrilimumab achieved a ≥1.2 decrease in disease activity score (DAS28-CRP) from baseline and the 100-mg dose demonstrated a significant effect versus placebo (23.1 vs. 6.7%). Besides, patients receiving mavrilimumab achieved higher American College of Rheumatology (ACR) response rates at week 24 (ACR20—69.2 vs. 40.0%, p = 0.005; ACR50—30.8 vs. 12.0%, p = 0.021; ACR70—17.9 vs. 4.0%, p = 0.030). Adverse events were generally mild or moderate in intensity. No significant hypersensitivity reactions, serious or opportunistic infections, or changes in pulmonary parameters were observed [50]. In the EARTH EXPLORER II study, 138 patients with active RA and had an inadequate response to tumour necrosis factor inhibitors were randomized to receive mavrilimumab 100 mg every 2 weeks or golimumab 50 mg every 4 weeks for 24 weeks. The difference in the numbers of patients achieving ACR20 response was not statistically different between groups (65.6 vs. 62%, p = 0.666) (NCT01715896). As a result, further large-scale studies are warranted to confirm the therapeutic potential of mavrilimumab and to determine its optimal position in the treatment algorithm of RA.
Intracellular targets in RA

Janus kinase-signal transducer and activator of transcription pathway

JAK is a receptor tyrosine kinase that mediates intracellular signalling through the transcription factor STAT. In humans, the JAK-STAT pathway is the principal signalling cascade for a wide variety of cytokines and growth factors [51–54]. Intracellular activation of JAK occurs when ligand binding induces the crosslinking of receptor subunits. Activated JAKs phosphorylate the tyrosine residues on the receptors, allowing the binding of STATs in the SRC2 homology domain. JAK then phosphorylates the tyrosine residues on the STATs, leading to dimerization and activation of the STATs. Activated STATs then migrate via the cytoplasm to translocate into the nucleus, where they induce transcription of target genes [54].

The JAK family comprises four members, JAK1, JAK2, JAK3 and Tyk2. JAK1, JAK2 and Tyk2 are expressed ubiquitously, while JAK3 has limited expression in haematopoietic cells [55]. JAK1 interacts with a wide variety of cytokines, through the common γ chain receptor subunit (IL-2 and IL-4 receptor family) and the glycoprotein-130 subunit. JAK1 is also involved in type 1 interferon signal transduction. JAK2 also interacts with cytokines through the glycoprotein-130 subunits, as well as other hormones including erythropoietin, thrombopoietin, prolactin and growth hormone. As a result, the use of JAK2 inhibitors may be associated with anaemia and thrombocytopenia. JAK3 interacts with many inflammatory cytokines through the common γ chain receptor subunit [56], and inactivating mutations in the common γ chain and JAK3 have been shown to cause X-linked severe combined immunodeficiency [57]. Patients with X-linked severe combined immunodeficiency have a significantly impaired adaptive immune system due to the absence of T cells and non-functional B cells (Table 1).

Many JAK inhibitors have been studied for the treatment of RA [58]. Tofacitinib, the first-in-class JAK inhibitor, has been shown to be efficacious in different clinical settings—it blocks JAK1 and JAK3 preferentially [59–64] (Table 2). In the ORAL standard trial, patients with an inadequate response to methotrexate were randomized to receive tofacitinib, adalimumab or placebo plus background methotrexate. At 6 months, patients receiving tofacitinib (5 or 10 mg twice daily) had less radiological progression. The mean changes in total modified Sharp score for tofacitinib at 5 and 10 mg twice daily were 0.12 and 0.06, respectively, versus 0.47 for placebo [60]. Patients with inadequate response to tumour necrosis factor inhibitors were evaluated in the ORAL step trial. The addition of tofacitinib (5 or 10 mg twice daily) to methotrexate (MTX), compared with placebo plus MTX, resulted in significantly higher ACR20 response rates (42, 48 vs. 24%, respectively) and greater reductions in the HAQ-DI scores at 3 months [61].

The relative safety of tofacitinib has generally appeared similar to that of biologic DMARDs, including increased risk of infections and liver function derangements, cytopenias, hyperlipidaemia and, possibly, increased serum creatinine levels. Gastrointestinal perforations have also been reported. The incidence was similar to the published data of tumour necrosis factor inhibitors and perhaps lower than that associated with tocilizumab. It has been postulated that this potential side effect could be due to a significant inhibition of IL-6 production. The risk of herpes zoster reactivation was found to be significantly increased in patients receiving tofacitinib. Data from the phase II, III and long-term extension studies showed that the incidence rate of herpes zoster reactivation was 4.4 per 100 patient-years in patients receiving tofacitinib, compared to 1.5 per patient-years in the placebo arm. The risk is substantially higher among Asians, the elderly and those using higher doses of glucocorticoids [65].

Baricitinib, another novel JAK inhibitor, has also been evaluated in several phase III clinical trials. It preferentially inhibits JAK1 and JAK2 and demonstrates efficacy in patients with RA in different clinical settings [66–69] (Table 3). In the RA-Beam trial, patients with active RA on background MTX were randomized to receive baricitinib 4 mg daily, adalimumab 40 mg every 2 weeks or placebo (switched to baricitinib at week 24) for 52 weeks. At week 12, patients receiving baricitinib were more likely to achieve ACR20 response compared with those receiving adalimumab or placebo (70 vs. 61 vs. 40%). The ACR20 response rates at week 12 in patients receiving 4 mg baricitinib and placebo were 70 and 40%, respectively. There were also greater reductions in the HAQ-DI scores and progression of mean total modified Sharp scores at 24 weeks [69]. Similar results were also demonstrated in the RA-BUILD trial. Patients with active RA and who had an inadequate response to conventional synthetic DMARDs were randomized to receive baricitinib (2 or 4 mg daily) or placebo. Patients receiving 4 mg baricitinib achieved higher ACR20 response rates than those receiving placebo at 12 weeks [66]. In addition, patients who had an inadequate response to tumour necrosis factor inhibitors also showed a significant improvement after receiving high-dose baricitinib. The ACR20 response rates at week 12 in patients receiving...
4 mg baricitinib and placebo were 55 and 27%, respectively [67]. To date, baricitinib is pending approval by the FDA and EMA.

Meanwhile, other JAK inhibitors are being evaluated in phase III clinical trials. Filgotinib developed by Galapagos NV/Gilead and ABT-494 by AbbVie are both selective JAK1 inhibitors. The use of these agents can theoretically reduce the risk of JAK2- and JAK3-associated adverse reactions. Both filgotinib and ABT-494 showed promising results in patients with RA in phase IIb studies [70–73], and phase III studies are being conducted to evaluate their therapeutic efficacies (Table 4).

### Bruton's tyrosine kinase pathway

Bruton’s tyrosine kinase (BTK) is another key intracellular kinase being actively investigated for the treatment of RA in addition to other immune-mediated disorders, e.g. SLE. It is a member of the Tec family of non-receptor tyrosine kinases with restricted expression in B cells and myeloid cells, such as

| Table 1 Cytokines and hormones activating the JAK pathway |
|----------------------------------------------------------|
| **JAK1** | **JAK2** | **JAK3** |
| Common γ chain receptor family | Common γ chain receptor family | | |
| IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 | IL-2, IL-4, IL-7, IL-9, IL-15, IL-21 | | |
| Gp130 receptor family | Gp130 receptor family | | |
| IL-6, IL-11, IL-27, IL-31 | IL-6, IL-11, IL-27, IL-31 | | |
| Interferon | Interferon | | |
| IFNα/β/γ | IFNα/β/γ | | |
| Hormones | | | |
| Erythropoietin | | | |
| Thrombopoietin | | | |
| Prolactin | | | |
| Growth hormone | | | |
| GM-CSF receptor family | | | |
| IL-3R, IL-5R, GM-CSF-R | | | |

| Table 2 Clinical trials of tofacitinib |
|--------------------------------------|
| **Study name** | **Number of subjects** | **Subject characteristics** | **Intervention** | **Primary endpoints** | **Results** |
| ORAL start [59] | 958 | MTX naive | Tofacitinib (5 or 10 mg) vs. MTX 20 mg per week | ACR70 response | 25.5, 37.7 vs. 12.0% |
| | | | | Mean change in modified total Sharp score | 0.2, <0.1 vs. 0.8 |
| ORAL scan [60] | 797 | MTX-IR | Tofacitinib (5 or 10 mg) vs. placebo | ACR20 response | 51.5, 61.8 vs. 25.3% |
| | | | | Mean change in modified total Sharp score | 0.12, 0.06 vs. 0.47a |
| | | | | Mean change in HAQ-DI | −0.40, −0.54 vs. −0.15 |
| | | | | DAS remission | 7.2, 16 vs. 1.6% |
| ORAL solo [63] | 611 | DMARD-IR* | Tofacitinib (5 or 10 mg) vs. placebo | ACR20 response | 59.8, 65.7 vs. 26.7% |
| | | | | Mean change in HAQ-DI | −0.50, −0.57 vs. −0.19 |
| | | | | DAS remission | 5.6, 8.7 vs. 4.4% (NS) |
| ORAL sync [64] | 792 | DMARD-IR* | Tofacitinib (5 or 10 mg) vs. placebo | ACR20 response | 52.1, 56.6 vs. 30.8% |
| | | | | Mean change in HAQ-DI | −0.44, −0.53 vs. −0.16 |
| | | | | DAS remission | 8.5, 12.5 vs. 2.6% |
| ORAL standard [62] | 717 | MTX-IR | Tofacitinib (5 or 10 mg) vs. adalimumab 40 mg q2w vs. placebo | ACR20 response | 51.5, 52.6, 47.2 vs. 28.3% |
| | | | | Mean change in HAQ-DI | 0.55, −0.61, 0.49 vs. −0.24 |
| | | | | DAS remission | 6.2, 12.5, 6.7 vs. 1.1% |
| ORAL step [61] | 399 | TNFi-IR | Tofacitinib (5 or 10 mg) vs. placebo | ACR20 response | 41.7, 48.1 vs. 24.4% |
| | | | | Mean change in HAQ-DI | −0.43, −0.46 vs. −0.18 |
| | | | | DAS remission | 6.7, 8.8 vs. 1.7% |

a At least 1 non-biologic or biologic DMARD#262

a Since tofacitinib 5 mg twice daily failed to show statistically significance for radiographic progression, and due to the step-down procedure applied to the primary efficacy endpoints, significance was not declared for the HAQ-DI and DAS remission
macrophages and dendritic cells [74]. It plays a crucial role in B cell development and activation. When an antigen binds to the B cell receptor, spleen tyrosine kinase (SYK) is activated and leads to subsequent phosphorylation of adaptor proteins recruiting PI3K to the plasma membrane. As a result, intracellular levels of phosphatidylinositol-3,4,5-triphosphate (PIP3) increases [75]. PIP3 binds to the pleckstrin homology domain of BTK and thereby promotes the recruitment of BTK to the plasma membrane [76]. Subsequent phosphorylation of BTK by the Src-kinases and SYK activates phospholipase C-γ2, which leads to nuclear factor κB and nuclear factor of activated T cells transcriptional activation [77]. Through these signalling pathways, BTK activation induces B cell survival, proliferation and differentiation into plasma cell. Mutations of the BTK genes are associated with the development of X-linked agammaglobulinaemia in human and X-linked immunodeficiency in mice [78, 79]. In addition to B cell receptor signalling, BTK is also associated with macrophage signalling through the FCγ receptors. In the absence of BTK, FCγ receptor-associated functions are impaired. In animal models, macrophages from mice with X-linked immunodeficiency produce less nitric oxide, TNF-α and IL-1β [80, 81].

Given that BTK is functionally active in both B cells and myeloid cell function, it is an attractive therapeutic target for RA. In particular, inhibiting the kinase activity of BTK would block multiple signalling pathways in different cell populations. In the CIA model, mice with mutations in BTK have decreased susceptibility to develop arthritis [82]. Similarly, FCγ receptor-deficient mice do not develop arthritis, even with the presence of auto-antibodies [83]. Consequently, several small molecule BTK inhibitors have been developed and demonstrated efficacy in animal models of RA [84]. However, only six BTK inhibitors are currently reported to be in clinical development for RA. All of the inhibitors selectively target the ATP-binding pocket of BTK, and the irreversible inhibitors covalently bind the cysteine residue in the active site of the kinase domain [85].

CC-292 is the first irreversible BTK inhibitor that has been evaluated in a phase II study. Seventy patients with active RA and had an inadequate response to methotrexate were included in the study. The primary endpoint was ACR20 response at week 12, and the results showed that CC-292 was non-inferior to placebo. In addition, CC-292 was well tolerated and did not cause any serious adverse events.

### Table 3
Clinical trial of baricitinib

| Study name       | Number of subjects | Subject characteristics | Intervention                                                                 | Primary endpoints       | Results        |
|------------------|--------------------|-------------------------|-----------------------------------------------------------------------------|-------------------------|----------------|
| RA-BEGIN [68]    | 588                | DMARD naive            | Baricitinib 4 mg + MTX 10-20 mg per week vs. baricitinib 4 mg vs. MTX 10-20 mg per week | ACR20 response          | 77 vs. 62%a   |
| RA-BEAM [69]     | 1307               | MTX-IR                  | Baricitinib 4 mg vs. adalimumab 40 mg q2w vs. placebo                       | ACR20 response          | 70 vs. 61% 40%b|
| RA-BUILD [66]    | 684                | DMARD-IR               | Baricitinib (2 or 4 mg) vs. placebo                                         | ACR20 response          | 62 vs. 39%e   |
| RA-BEACON [67]   | 527                | TNF-IR                  | Baricitinib (2 or 4 mg) vs. placebo                                         | ACR20 response          | 55 vs. 27%c   |
| RA-BEYOND        | Estimated 3073     |                         |                                                                              | 1 drug-related adverse event or any serious adverse events | Ongoing        |

a The primary endpoint is a non-inferiority comparison of baricitinib monotherapy to MTX monotherapy

b The primary endpoint is a superiority comparison of baricitinib therapy to placebo. Baricitinib therapy is compared with adalimumab based on non-inferiority design

c The primary endpoint is the comparison between baricitinib 4mg and placebo

### Table 4
Clinical trials of filgotinib and ABT-494

| Study drug | Estimated enrolment | Subject characteristics | Intervention                                                                 | Primary endpoints       | ClinicalTrials.gov identifier |
|------------|---------------------|-------------------------|-----------------------------------------------------------------------------|-------------------------|------------------------------|
| Filgotinib | 1200                | MTX naïve               | Filgotinib + MTX vs. filgotinib vs. MTX                                     | ACR20 response          | NCT02886728                  |
|            | 1650                | MTX-IR                  | Filgotinib vs. adalimumab vs. placebo                                       | ACR20 response          | NCT02889796                  |
|            | 423                 | bDMARD-IR               | Filgotinib vs. placebo                                                      | ACR20 response          | NCT02873936                  |
| ABT-494    | 975                 | MTX naïve               | ABT-494 vs. MTX                                                             | ACR20 response; DAS28-CRP remission | NCT02706873          |
|            | 1500                | MTX-IR                  | ABT-494 vs. adalimumab vs. placebo                                         | ACR20 response          | NCT02629159                  |
|            | 600                 | MTX-IR                  | ABT-494 vs. MTX                                                             | ACR20 response; DAS28-CRP LDA | NCT02706951                  |
|            | 600                 | csDMARD-IR              | ABT-494 vs. placebo                                                         | ACR20 response; DAS28-CRP LDA | NCT02675426                  |
PI3Ks are lipid-signalling kinases that phosphorylate phosphoinositides to produce phosphorylated inositol lipids. PI3Ks are classified into class I, II and III according to their structures, regulations and lipid substrate specificities [87, 88]. To date, only the functions of class I PI3Ks have been well characterized, whereas the roles of class II and III PI3Ks in humans are yet to be elucidated. Class I PI3Ks, which include PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, catalyze the phosphorylation of phosphatidylinositol-4,5-bisphosphate to phosphatidylinositol-3,4,5-trisphosphate (Table 5). Through subsequent signalling cascades, class I PI3Ks control many cellular functions, such as growth, proliferation, survival and apoptosis, as well as leukocyte adhesion and migration. PI3Kα and PI3Kβ are ubiquitously expressed, whereas PI3Kδ and PI3Kγ are preferentially expressed in leukocytes and play a crucial role in innate and adaptive immune response.

In T cells, class I PI3Ks are activated by T cell receptor (TCR) or IL-2 receptor engagement. In p110γ knockout T cells, TCR-mediated early signalling is relatively unaffected, but they proliferate less after stimulation with CD3-specific antibody and produce lower levels of cytokines in vitro [89]. Similarly, PI3Kγ kinase inactive knockin mice also show reduced T cell proliferation and activation in vitro, and impaired antigen-specific T cell responses in vivo [90]. In addition, PI3Kδ is involved in the differentiation of T cells. In animal models, p110δ mutant mice had impaired differentiation along the T helper (Th) 1 and Th 2 lineage [91] and exhibited a significant decrease in T helper 2 cytokine responses [92]. P110δ mutant mice also had reduced regulatory T cell (Treg) populations in the spleen and lymph nodes, implicating PI3Kδ in the maintenance of Treg in the periphery. Moreover, Treg cells with inactive PI3Kδ had attenuated secretion of IL-10 to suppress T cell proliferation in vitro [93].

PI3Kδ is essential for B cell development and function as it generates survival signals even without antigen binding to the B cell receptors [94–96]. In animal models, PI3Kδ mutant mice have significant reductions in the IgM producing B cell and marginal zone B cell populations [96]. B cell proliferative responses to IL-4 stimulation and T cell-independent antibody responses in PI3Kδ mutant mice are also attenuated [97, 98]. Furthermore, B cells deficient in p110δ showed diminished chemotactic responses to CXCL13 and CXCR5-dependent B cell homing to Peyer’s patches [99].

In common with other leucocytes, class I PI3Ks are markedly enriched in neutrophils. In p110γ knockout mice, neutrophils migrate less efficiently towards chemokines and chemoattractants, such as complement C5a and bacterial peptide N-formyl-methionyl-leucyl-phenylalanine (fMLP) [100, 101]. Neutrophils with inactive p110γ also demonstrated impaired reactive oxygen species production [101] and neutrophil respiratory burst in response to fMLP [102]. Apart from neutrophils, dendritic cells from p110γ knockout mice also developed impaired migration to the site of inflammation [103]. Although the involvement of PI3Kδ in neutrophil functions has been controversial, PI3Kδ may have a role in promoting IL-6 release in response to cKit stimulation on dendritic cells [104].

Based on these findings, PI3Kδ and PI3Kγ have attracted considerable interest as pharmacological targets in the treatment of RA [105, 106]. In the CIA model, mice treated with a p110γ selective inhibitor show significant reduction in joint inflammation. Histological measures of synovial inflammation and neutrophil infiltration in arthritic joints are also significantly attenuated [107]. PI3Kγ is also implicated in the regulation of synovial fibroblasts, in which p110γ-specific inhibitor show significant reduction in joint inflammation. In vitro analyses confirmed that the decreased invasiveness of fibroblasts is mediated by reduced phosphorylation of Akt and extracellular signal-regulated kinase. Similar findings using a PI3Kγ-specific inhibitor in human synovial

| PI3K isoform | Catalytic subunit | Regulatory subunits | Substrate | Product |
|--------------|-------------------|---------------------|-----------|---------|
| Class IA     | PI3Kα             | p110α               | p85α, p85β, p55α, p55γ, p50α | PI-4,5-P2 | PIP3   |
|              | PI3Kβ             | p110β               |           |         |        |
|              | PI3Kδ             | p110δ               |           |         |        |
| Class IB     | PI3Kγ             | p110γ               | p101, p84 | PI-4,5-P2 | PIP3   |
|              | PIK3-C2           |                     | PI-4-P    | PI-3-AP2|        |
|              | PIK3-C3           |                     | PI-3-P    |         |        |
|              | PIK3-C2           |                     | PI-3-P    |         |        |
| Class III    | VPS34             | P150                | PI        | PI-3-P  |        |

Table 5 Isoforms of PI3K
fibroblasts from patients with RA who exhibit disease-specific up-regulation of PI3Kγ was also confirmed in this study [108]. A recent study also reported the role of PI3K signalling pathway in synovial angiogenesis in the CIA model. Hypoxia-inducible factor 1α and vascular endothelial growth factor are up-regulated through PI3K signalling and mediates subsequent neovascularization of the synovium [109].

At present, PI3K inhibition is a major focus in the field of oncology. Idelalisib, the first-in-class PI3K inhibitor, appears efficacious in refractory chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma and has provided some safety data concerning PI3K inhibition [110–113]. Many pharmaceutical companies are exploring the potential of PI3K inhibitors in autoimmune diseases, like RA. However, no PI3K inhibitor has yet entered a clinical development programme to our knowledge.

Neuropathways in RA

The reciprocal effects of the nervous system on immunity has raised recent interest. It is well known that the nervous system regulates inflammation through peripheral nerves and a variety of neurotransmitters and neuropeptides. In animal models, peripheral denervation attenuates joint inflammation in mice with adjuvant induced arthritis [114]. An imbalance of the autonomie nervous system has been implicated in many inflammatory conditions. In general, activation of para-sympathetic nervous system mediates an anti-inflammatory response, while the sympathetic nervous system may have both pro-inflammatory and anti-inflammatory properties [115]. The para-sympathetic nervous system, through the vagus nerve, exerts anti-inflammatory actions. In a mouse model, electrical stimulation of the peripheral part of the vagus nerve significantly decreases serum TNF-α levels in rats with bilateral cervical vagotomy. In vitro studies showed that acetylcholine (ACh) inhibits pro-inflammatory cytokine release by the macrophages in a dose dependent fashion [116]. Subsequent research had identified the neuronal type α7-ACh receptor subtype as the essential regulator of the anti-inflammatory effects mediated by the para-sympathetic nervous system [117]. α7-ACh receptors are not only found on neurons but also widely expressed in immune cells and fibroblast like synoviocytes [118–120]. In the CIA model, administration of a specific α7-ACh receptor agonist showed effective attenuation of arthritis and systemic inflammatory responses [121, 122]. Conversely, α7-ACh receptor knockout mice developed more severe arthritis compared with the wild type controls [123]. Apart from the effects mediated by immune cells, activation of the α7-ACh receptor in the fibroblast like synoviocytes also suppresses the production of pro-inflammatory cytokines [119, 124]. The spleen also plays an important role in the regulation of systemic inflammation. Although there is no evidence showing that lymphoid organs are directly innervated by the para-sympathetic innervation, studies have shown that the spleen is able to receive signals from the para-sympathetic system and vagus nerve activation may inhibit TNF-α production by splenic macrophages via the celiac superior mesenteric plexus [125, 126]. Recently a clinical trial provided proof of concept that vagal nerve stimulation could be therapeutically feasible in RA [127]. In this study, 17 patients with RA received vagus nerve stimulation. At day 42, DAS28-CRP levels significantly improved from baseline (6.05 ± 0.18 vs. 4.16) and the results were more robust in biologic naive patients. The proportions of patients achieving ACR20, ACR50 and ACR70 response were 71.4, 57.1 and 28.6%, respectively. Among patients who responded to vagus nerve stimulation, their serum IL-6 levels were significantly reduced from baseline and the reduction in IL-6 levels correlated with the improvement in disease activity [127].

The sympathetic nervous system, in turn, mediates its effect on the immune system via catecholamine production. Both primary and secondary lymphoid organs are innervated by the sympathetic nervous system [128, 129]. Lymphocytes primarily express the β2 adrenergic receptors while cells of the innate immune systems express α1, α2 and β2 adrenergic receptors [129]. The effect of sympathetic nervous system on the immune system is more complex. In general, sympathetic activation is able to inhibit the development of a Th1 immune response [128]. Patients with RA have an imbalance of the autonomic nervous system, with increased sympathetic and reduced para-sympathetic activities [130]. However, peripheral mononuclear cells from patients with RA express lower levels of β2 adrenergic receptors and, therefore, less effective in suppressing T cell activation and proliferation via β2 adrenergic activation [131]. In contrary, catecholamines mediate their effects through α1 adrenergic receptors on the peripheral mononuclear cells [132], leading to increased production of IL-6 [133]. In addition, α2 stimulation promotes the proliferation of fibroblast-like synoviocytes in patients with RA and subsequent production of pro-inflammatory cytokines [134]. At present, modulations of the sympathetic nervous system yield inconsistent effects in animal arthritis models, and none of them has been evaluated in clinical development programme.

Long-term remission strategies and immune homeostasis

Dendritic cell therapeutics

Dendritic cells (DCs) play a key role in both the innate and adaptive immunity. In the periphery, DCs exist as immature cells and undergo differentiation after exposure to pro-inflammatory cytokines, immune complexes or pathogens and endogenous inflammatory factors that are recognized by
the Toll-like receptors. Mature DCs then migrate to lymph nodes and present antigens on the MHC molecules to the naive T cells. Cytokines produced by the DCs also promote the differentiation and maturation of T and B cells [135]. DCs are important for maintaining intra-thymic and peripheral tolerance. Immature DCs recognize and phagocytose apoptotic cells [136], rendering DCs tolerogenic as they produce immunosuppressive cytokines and promote cross tolerance of the T cells by inducing T cell anergy, clonal deletion or Treg and suppressor T cell differentiation [137–139]. In normal circumstances, this process does not result in DC maturation. However, failed clearance of apoptotic cells or exposure to maturation signals may induce the production of immunogenic DCs [140, 141].

In patients with RA, the synovial DCs are activated in response to pro-inflammatory cytokines, with up-regulation of MHC and co-stimulatory molecule expression [142, 143]. They also produce IL-12 and IL-23 to potentially promote the differentiation of Th1 and Th17 cell [144]. Treatment with TNFi not only ameliorates the clinical symptoms of RA but also reduces the number of activated DCs and inhibits DC maturation [145, 146]. These observations support the strategy of targeting dendritic cells for the treatment of RA.

In CIA models, administration of low doses of semi-mature DCs inhibits disease progression by enhancing Treg populations and suppresses antigen-specific Th1- and Th17-mediated immunity [147]. Treatment of CIA mice with tolerogenic DCs modified by tacrolimus significantly inhibited the severity and progression of disease with the alteration of the proportion of the Th1 and Th17 in the spleen [148]. Similar results have been confirmed by administration of tolerogenic DCs generated by GM-CSF and IL-4 stimulations [149]. These data provide a better understanding and consolidate the role of tolerogenic DCs in the treatment of RA [150, 151].

The first clinical study using tolerogenic DCs was carried out in the University of Queensland. In this phase 1 study, tolerogenic DCs were generated by treatment of monocyte-derived DCs with an inhibitor of NFkB signalling. These tolerogenic DCs are deficient for CD40 expression but express high levels of CD86 [152]. After priming with citrullinated peptide antigens, the tolerogenic DCs were injected intradermally to 18 patients with RA positive for HLA-DR expression. The treatment was well tolerated with no major adverse effects. The results of another phase 1 trial were published recently. It is a randomized, unblinded, placebo-controlled, dose-escalation phase I study. The tolerogenic DCs were generated by pharmacological modulation of monocyte-derived DCs from patients with dexamethasone and vitamin D₃, together with a Toll-like receptor-4 agonist. The tolerogenic DCs express high levels of MHC class II molecules and intermediate levels of co-stimulatory molecules CD80 and CD86 and produce high levels of IL-10 and TGF-β [150]. Instead of intradermal injection, 13 patients received three different doses of tolerogenic DCs through intra-articular injection under arthroscopic guidance. The primary objective was to assess the safety of intra-articular injection of tolerogenic DCs in patients with RA. No patient developed an exacerbation of arthritis in the target knee within 5 days of treatment. At day 14, arthroscopic synovitis was present in all participants except for one who received 10 × 10⁶ tolerogenic DCs. Two patients receiving 3 × 10⁶ tolerogenic DCs and one patient receiving 10 × 10⁶ tolerogenic DCs demonstrated improvement in vascularity on day 14, whereas no improvement was seen in six patients receiving 1 × 10⁶ tolerogenic DCs or placebo. Synovitis improved in one of three patients in each of the 1 × 10⁶ and 3 × 10⁶ tolerogenic DC cohorts and in both assessable patients in the 10 × 10⁶ tolerogenic DC cohorts. There were no trends in DAS28 or HAQ score or consistent immunomodulatory effects in peripheral blood [153].

Although tolerogenic DC therapy demonstrates promising results in patients with RA, there are some important issues to be tackled for further clinical evaluation. Administration of tolerogenic DC therapy in patients with established autoimmunity may be less efficacious, and therefore, it should perhaps ideally be given to the patient with RA as early as possible. However, the timing of the treatment is still controversial as potentially elevation of regulatory pathways may suffice. Secondly, the selection of auto-antigens for the generation of tolerogenic DCs may be critical for the efficacy of tolerogenic DC therapy in patients with RA. However, these auto-antigens are not always detected and little is known about the immunodominant profile of these auto-antigens in association with RA pathogenesis and disease progression. Besides, careful consideration should be given to the dose of tolerogenic DCs administered because a high dose of tolerogenic DCs may be potentially immunogenic [154–156]. At present, there is no reliable biomarker of tolerance induction that can be measured after administration of tolerogenic DC therapy. Therefore, further studies are necessary for the development of this immunotherapy.

**Conclusion**

Recent advances in the understanding of the pathophysiology of RA facilitate the development of new therapeutic agents. Inhibition of the JAK pathway has already been used in clinical practice, and more selective JAK inhibitors are expected to be available in the near future. The therapeutic potential of BTK inhibitors is being evaluated in phase II studies. As a result, it is expected that over time we will see a balance of therapeutic interventions between biologic and small molecule targeted synthetic DMARDs.
Compliance with ethical standards

Conflict of interest  There is no conflict of interest for TC. IBM has received honoraria or research funding from AbbVie, BMS, Janssen, Novartis, Pfizer, Roche and UCB.

Open Access  This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1.  Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC (2003) Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 107(9):1303–1307
2.  Semb AG, Kvien TK, Aastveit AH, Jungen I, Pedersen TR, Walldius G, Holme I (2010) Lipids, myocardial infarction and ischaemic stroke in patients with rheumatoid arthritis in the Apolipoprotein-related Mortality RISk (AMORIS) study. Ann Rheum Dis 69(11):1996–2001
3.  Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentschel MA, Gonzalez-Gay MA, Provan S, Semb A, Sidiro Poulos P, Kitas G, Smulders YM, Soubrier M, Szkanezcz Z, Sattar N, Nurmovehmed MT (2010) EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 69(2):325–331
4.  Meune C, Touze E, Trinquart L, Allanore Y (2009) Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: a systematic review and meta-analysis of cohort studies. Rheumatology (Oxford) 48(10):1309–1313
5.  Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Sattar N, Nurmohamed MT (2010) Prognostic factors for cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 59(12):1690–1697
6.  Askling J, Fored CM, Brandt L, Baecklund E, Berclaz PY, Fautrel B, Erskine L, Letts J, Lysolm J, Rantapaa-Dahlqvist S, Saxne T, Klareskog L (2005) Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64(10):1421–1426
7.  Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, Holmstrom H, Jacobsson LT (2005) Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64(5):699–703
8.  Thomas E, Brewster DH, Black RJ, Macfarlane GJ (2000) Risk of malignancy among patients with rheumatic conditions. Int J Cancer 88(3):497–502
9.  Smolen JS, Breedveld FC, Burmester GR, Bykerk V, Dougados M, Emery P, Kvien TK, Navarro-Compan MV, Oliver S, Schols M, Scholte-Voshaar M, Stamm T, Stoffer T, Takeuchi T, Aletaha D, Andreu JL, Aringer M, Bergman M, Betteridge N, Bijlsma J, Burkhart H, Cardiel M, Combe B, Durez P, Fonseca J, Gibofsky A, Gomez-Reino JJ, Graninger W, Hannonen P, Harauo B, Kouloumas M, Landewe R, Martín-Mola E, Nash P, Ostergaard M, Ostor A, Richards P, Sokka-Islser T, Thorne C, Tzioufas AG, von Vollenhoven R, de Wit M, van der Heijde D (2016) Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 75(1):3–15
10.  van Eijk JC, Nielen MM, van der Horst-Bruinsma I, Tijhuis GJ, Boers M, Dijkmans BA, van Schaardenburg D (2012) Aggressive therapy in patients with early arthritis results in similar outcome compared with conventional care: the STREAM randomized trial. Rheumatology (Oxford) 51(4):686–694
11.  Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, van Riel P, Fransen J, van de Laar MA (2012) A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry. Ann Rheum Dis 71(6):845–850
12.  Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Kerstens PJ, Nielen MM, Vos K, van Schaardenburg D, Speyer I, Seys PE, Breedveld FC, Allaart CF, Dijkmans BA (2010) DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. Ann Rheum Dis 69(1):55–69
13.  Soubrier M, Lukas C, Sibilia J, Fautrel B, Roux F, Gossec L, Patterson S, Dougados M (2011) Disease activity score-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis: data from the GUEPARD trial and ESPOIR cohort. Ann Rheum Dis 70(4):611–615
14.  Gullick NJ, Oakley SP, Zain A, Gibbons T, Jones T, Mistlin A, Rees JD, Panayi GS, Kirkham BW (2012) Goal-directed therapy for RA in routine practice is associated with improved function in patients with disease duration up to 15 years. Rheumatology (Oxford) 51(4):759–761
15.  Brenol CV, da Chakir MR, Andrade NP, Toni M, Laurindo IM, Brenol JC, Xavier RM (2015) Daily practice feasibility and effectiveness of treating long-standing rheumatoid arthritis to target with synthetic disease-modifying antirheumatic drugs: a prospective cohort study. Clin Rheumatol 34(10):1781–1785
16.  Thiele K, Huscher D, Bischoff S, Spalhing-Mestekemper S, Backhaus M, Aringer M, Kollmann M, Zink A, German Collaborative Arthritis (2013) Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis. Ann Rheum Dis 72(7):1194–1199
17.  Provan SA, Semb AG, Hisdal J, Stranden E, Agewall S, Dagfinrud H, Angel K, Arat D, Kvien TK (2011) Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Ann Rheum Dis 70(5):812–817
18.  Pavelka K, Chon Y, Newmark R, Lin SL, Baumgartner S, Erondou N (2015) A study to evaluate the safety, tolerability, and efficacy of brodalumab in subjects with rheumatoid arthritis and an inadequate response to tumor necrosis factor inhibitors. Arthritis Care & Research 66(7):1693–1704
19.  Genovese MC, Braun DK, Erickson JS, Berclaz PY, Banerjee S, Hefferman MP, Carlier H (2016) Safety and efficacy of open-label subcutaneous ixekizumab treatment for 48 weeks in a phase II study in biologic-naive and TNF-IR patients with rheumatoid arthritis. J Rheumatol 43(2):289–297
20.  Genovese MC, Greenwald M, Chor CS, Berman A, Jin L, Cameron GS, Benichou O, Xie L, Braun D, Berclaz PY, Banerjee S (2014) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis & Rheumatology 66(7):1693–1704
21.  Blanco FJ, Moricke R, Dokoupilova E, Coddington C, Neal J, Andersson M, Rohrer S, Richards H. (2017) Secukinumab in active rheumatoid arthritis: a randomized, double-blind placebo and active comparator controlled phase 3 study. Arthritis Rheumatol. doi:10.1002/art.40070
22. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Coddin CE, Kellner H, Ikawa T, Hugot S, Ligozino in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study. J Rheumatol 41(3):414–421

23. Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Mazurov V, Aelion JA, Lee SH, Coddin CE, Kellner H, Ikawa T, Hugot S, Mpho D (2013) Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled study. Ann Rheum Dis 72(6):863–869

25. Bussolino F, Wang JM, Defilippi P, Turrini F, Sanavio F, Edgell CJ, Aglietta M, Arese P, Mantovani A (1989) Granulocyte- and granulocyte-macrophage-colony stimulating factors induce human endothelial cells to migrate and proliferate. Nature 337(6206):471–473

26. Leizer T, Cebon J, Layton JE, Hamilton JA (1990) Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 76(10):1989–1996

27. Campbell IK, Novak U, Cebon J, Layton JE, Hamilton JA (1991) Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1. J Immunol 147(4):1238–1246

28. Hamilton JA (2008) Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 8(7):533–544

29. Hansen G, Hercus TR, McClure BJ, Stomski FC, Dottore M, Powell J, Ramshaw H, Woodcock JM, Xu Y, Guthridge M, McKinstry WJ, Lopez AF, Parker MW (2008) The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 134(3):496–507

30. Jenkins BJ, Blake TJ, Gonda TJ (1998) Saturation mutagenesis of the beta subunit of the human granulocyte-macrophage colony-stimulating factor receptor shows clustering of constitutive mutations, activation of ERK MAP kinase and STAT pathways, and differential beta subunit tyrosine phosphorylation. Blood 92(6):1989–2002

31. Sato N, Sakamaki K, Terada N, Arai K, Miyajima A (1993) Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 12(11):4181–4189

32. Fleetwood AJ, Cook AD, Hamilton JA (2005) Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 25(5):405–428

33. Fleetwood AJ, Lawrence T, Hamilton JA, Cook AD (2007) Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol 178(8):5245–5252

34. Xu Y, Zhan Y, Lew AM, Naik SH, Kershaw MH (2007) Differential development of murine dendritic cells by GM-CSF versus Flk3 ligand has implications for inflammation and trafficking. J Immunol 179(11):7577–7584

35. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O’Garra A, Liu YJ (2002) The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 195(7):953–958

36. Li BZ, Ye QL, Xu WD, Li JH, Ye DQ, Xu Y (2013) GM-CSF alters dendritic cells in autoimmune diseases. Autoimmunity 46(7):409–418

37. Conti L, Gessani S (2008) GM-CSF in the generation of dendritic cells from human blood monocyte precursors: recent advances. Immunobiology 213(9–10):859–870

38. Lebre MC, Tak PP (2008) Dendritic cell subsets: their roles in rheumatoid arthritis. Acta reumatologica portuguesa 33(1):35–45

39. Bell AL, Magill MK, McKane WR, Kirk F, Irvine AE (1995) Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 15(4):177–182

40. Field M, Clinton L (1993) Expression of GM-CSF receptor in rheumatoid arthritis. Lancet 342(8881):1244

41. Berenbaum F, Rajzbaum G, Amor B, Toubert A (1994) Evidence for GM-CSF receptor expression in synovial synovium. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies. Eur Cytoine Netw 5(1):43–46

42. Jang J, Lim DS, Choi YE, Jeong Y, Yoo SA, Kim WU, Bae YS (2006) MLN51 and GM-CSF involvement in the proliferation of fibroblast-like synoviocytes in the pathogenesis of rheumatoid arthritis. Arthritis Research & Therapy 8(6):R170

43. Torchinsky MB, Garauje J, Martin AP, Blander JM (2009) In innate immune recognition of infected apoptotic cells directs TH1 cell differentiation. Nature 458(7234):78–82

44. MacDonald KP, Pettit AR, Quinn C, Thomas GJ, Thomas R (1999) Resistance of rheumatoid synovial dendritic cells to the immunosuppressive effects of IL-10. J Immunol 163(10):5599–5607

45. Radstake TR, van Lent PL, Pesman GJ, Blom AB, Sweep FG, Ronneveld J, Adema GJ, Barrera C, van den Berg WB (2004) High production of proinflammatory and TH1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon Fc gamma R triggering. Ann Rheum Dis 63(6):696–702

46. Tsark EC, Wang W, Teng YC, Arkfeld D, Dodge GR, Kovats S (2002) Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 169(11):6625–6633

47. Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA (2001) Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 3(5):293–298

48. Cornish AL, Campbell IK, McKenzie BS, Chatfield S, Wicks IP (2009) G-CSF and GM-CSF as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 5(10):554–559

49. Avci AB, Feist E, Burmester GR (2014) Targeting GM-CSF in rheumatoid arthritis. Clin Exp Rheumatol 34(4 Suppl 98):39–44

50. Burmester GR, Weinblatt ME, McInnes IB, Porter D, Barbarash O, Vatutin M, Szombati I, Esfandiari E, Sleeman MA, Kane CD, Cavet G, Wang B, Godwood A, Magrini F, E.S. Group (2013) Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 144(8):5252–5259

51. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L (2000) The Jak-STAT pathway. Mol Immunol 37(5–6):43–54

52. Schindler C, Levy DE, Decker T (2007) JAK-STAT signaling: implications for CSF blockade in inflammation. J Immunol 179(11):7577–7584

53. Imada K, Leonard WJ (2000) The IL-10 signaling pathway. J Cell Sci 117(Pt 8):1281–1283

54. Yamaoka K, Saharinen P, Pesu M, Holt VE, 3rd, Silvennoinen O, O’Shea JJ (2004) The Janus kinases (Jaks). Genome Biol 5(12):253
83. Kleinman S, Martinsson P, Heyman B (2000) Induction and suppression of collagen-induced arthritis is dependent on distinct fgamma receptors. J Exp Med 191(9):1611–1616
84. Evans EK, Tester R, Aslanian S, Karp R, Sheets M, Labenski MT, Pan Z, Scheerens H, Li SJ, Schultz BE, Sprengeler PA, Burrill LC, Foster FM, Traer CJ, Abraham SM, Fry MJ (2003) The PI3K isoforms p110gamma and p110delta are essential for pre-B cell receptor signaling and B cell development. J Immunol 170(7):3122–3128
85. Condliffe AM, Davidson K, Anderson KE, Ellson CD, Crabbe T, Okkenhaug K, Vanhaesebroeck B; Turner M, Webb L, Wymann MP, Hayer S, Pundt N, Peters MA, Wunrau C, Kuhnel I, Neugebauer MP, Hirsch E, Mantovani A,佐川 S, 藤村 F, 矢野 K, 佐藤 S, 古泽 S (2004) Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J 23(17): 3505–3515
86. Banham-Hall E, Clatworthy MR, Okkenhaug K (2012) The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 6:245–258
87. Camps M, Hucke T, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7(3):191–201
88. Yang Q, Modip MP, Newcomb T, Queva C, Gandhi V (2015) Defective PI3Kgamma regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J Leukoc Biol 83(4):814–823
89. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG (2004) Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 173(4):2236–2240
90. Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP, Hirsch E, Rucke T, Camps M, Rommel C, Jackson SP, Chilvers ER, Stephens LR, Hawkins PT (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432–1440
91. Del Prete A, Verri W, Dunder E, Otero K, Barberis L, Luini W, Bemascioni S, Sironi M, Santoro A, Garlanda C, Facchetti F, Wymann MP, Vecchi C, Hirsch E, Mantovani A,佐川 S (2004) Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J 23(17): 3505–3515
92. Krishnamoorthy N, Oriss TB, Paglia M, Fei M, Yearlagadda M, Vanhaesebroeck B, Ray A, Ray P (2008) Activation of e-kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 14(5):565–573
93. Rommel C, Camps M, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7(3):191–201
94. Banham-Hall E, Clatworthy MR, Okkenhaug K (2012) The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 6:245–258
95. Camps M, Rucke T, Ji H, Ardissonne V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gremener D, Perrin D, Leroy D, Vetze P, Hirsch E, Wymann MP, Karchin R, Schwarz MK, Rommel C (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11(9):936–943
96. Hayer S, Pundt N, Peters MA, Wunrau C, Kuhnel I, Neugebauer MP, Hirsch E, Wymann MP, Karchin R, Schwarz MK, Rommel C (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11(9):936–943
97. Layton ST, Carpinino N, Takahashi Y, Piekorz R, Chao JR, Carpinino N, Wang D, Ihle JN (2002) Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 22(4):8580–8591
98. Dubois N, D’Souza S, Behrens S, Yang Y, Moskowitz JR, Zhu Z, 佐川 S, 佐藤 S (2002) Essential, nonredundant role for the phosphoinositide 3-kinase p110delta in signaling by the B-cell receptor complex. Mol Cell Biol 22(4):8580–8591
99. Clayton E, Bardi G, Bell SE, Chantry D, Downes CP, Gray A, Humphries LA, Rawlings D, Reynolds H, Vigo E, Turner M (2002) A crucial role for the p110delta subunit of phosphatidylinositol 3-kinase in B cell development and activation. J Exp Med 196(6):753–763
100. Thomas MS, Mitchell JS, DeNucci CC, Martin AL, Shimizu Y (2008) The p110gamma isoform of phosphatidylinositol 3-kinase regulates migration of effector CD4 T lymphocytes into peripheral inflammatory sites. J Leukoc Biol 83(4):814–823
101. Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG (2004) Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol 173(4):2236–2240
102. Okkenhaug K, Vanhaesebroeck B, Turner M, Webb L, Wymann MP, Hirsch E, Rucke T, Camps M, Rommel C, Jackson SP, Chilvers ER, Stephens LR, Hawkins PT (2005) Sequential activation of class IB and class IA PI3K is important for the primed respiratory burst of human but not murine neutrophils. Blood 106(4):1432–1440
103. Del Prete A, Verri W, Dunder E, Otero K, Barberis L, Luini W, Bemascioni S, Sironi M, Santoro A, Garlanda C, Facchetti F, Wymann MP, Vecchi C, Hirsch E, Mantovani A,佐川 S (2004) Defective dendritic cell migration and activation of adaptive immunity in PI3Kgamma-deficient mice. EMBO J 23(17): 3505–3515
104. Krishnamoorthy N, Oriss TB, Paglia M, Fei M, Yearlagadda M, Vanhaesebroeck B, Ray A, Ray P (2008) Activation of e-kit in dendritic cells regulates T helper cell differentiation and allergic asthma. Nat Med 14(5):565–573
105. Rommel C, Camps M, Ji H (2007) PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol 7(3):191–201
106. Banham-Hall E, Clatworthy MR, Okkenhaug K (2012) The therapeutic potential for PI3K inhibitors in autoimmune rheumatic diseases. Open Rheumatol J 6:245–258
107. Camps M, Rucke T, Ji H, Ardissonne V, Rintelen F, Shaw J, Ferrandi C, Chabert C, Gillieron C, Francon B, Martin T, Gremener D, Perrin D, Leroy D, Vetze P, Hirsch E, Wymann MP, Karchin R, Schwarz MK, Rommel C (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11(9):936–943
108. Hayer S, Pundt N, Peters MA, Wunrau C, Kuhnel I, Neugebauer MP, Hirsch E, Wymann MP, Karchin R, Schwarz MK, Rommel C (2005) Blockade of PI3Kgamma suppresses joint inflammation and damage in mouse models of rheumatoid arthritis. Nat Med 11(9):936–943
109. Hayer S, Pundt N, Peters MA, Wunrau C, Kuhnel I, Neugebauer K, Strieetholt S, Zwerina J, Korb A, Penninger J, Joosten LA, Gay S, Rucke T, Schett G, Pap T (2009) PI3Kgamma regulates cartilage damage in chronic inflammatory arthritis. FASEB J 23(12): 4288–4298
110. Zou L, Zhang G, Liu L, Chen C, Cao X, Cai J (2016) Relationship between PI3K pathway and angiogenesis in CIA rat synovium. Am J Transl Res 8(7):3141–3147
111. Sujobert P, Rioufol C, Salles GA (2016) Idelalisib: targeting the PI3 kinase pathway in non-Hodgkin lymphoma. Cancer J 22(1): 12–16
112. Nair KS, Cheson B (2016) The role of idelalisib in the treatment of relapsed and refractory chronic lymphocytic leukemia. Ther Adv Hematol 7(2):69–84
113. Barrientos JC (2016) Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential. Onco Targets Ther 9:2945–2953
114. Yang Q, Modip P, Newcomb T, Queva C, Gandhi V (2015) Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res 21(7):1537–1542
114. Courtright LJ, Kuzell WC (1965) Sparing effect of neurological deficit and trauma on the course of adjuvant arthritis in the rat. Ann Rheum Dis 24(4):360–368

115. Koopman FA, Stoof SP, Straub RH, Van Maanen MA, Vervoordeldonk MJ, Tak PP (2011) Restoring the balance of the autonomic nervous system as an innovative approach to the treatment of rheumatoid arthritis. Mol Med 17(9–10):937–948

116. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, Wang H, Abumrad N, Eaton JW, Tracey KJ (2000) Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 405(6785):458–462

117. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ (2003) Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 421(6921):384–388

118. de Jonge WJ, Ulloa L (2007) The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 151(7):915–929

119. van Maanen MA, Stoof SP, van der Zanden EP, de Jonge WJ, Janssen RA, Fischer DF, VandeGhinste N, Blys R, Vervoordeldonk MJ, Tak PP (2009) The alpha7 nicotinic acetylcholine receptor on fibroblast-like synoviocytes and in synovial tissue from rheumatoid arthritis patients: a possible role for a key neurotransmitter in synovial inflammation. Arthritis Rheum 60(5):1272–1281

120. Westman M, Engstrom M, Catrina AI, Lampa J (2009) Cell specific synovial expression of nicotinic alpha 7 acetylcholine receptor in rheumatoid arthritis and psoriatic arthritis. Scand J Immunol 70(2):136–140

121. van Maanen MA, Lebre MC, van der Poll T, LaRosa G, Elbaum RS, van Maanen MA, Lebre MC, van der Poll T, LaRosa GJ, Elbaum (2007) Functional alpha 1-adrenergic receptors on leucocytes of patients with polycyclic juvenile rheumatoid arthritis. J Neuroimmunol 71(1–2):223–226

122. Li T, Zuo X, Zou Y, Wang Y, Zhuang H, Zhang L, Zhang H, Xiao X (2010) The vagus nerve and nicotinic receptors involve inhibition of HMGBl release and early pro-inflammatory cytokines function in collagen-induced arthritis. J Clin Immunol 30(2):213–220

123. van Maanen MA, Stoof SP, Larosa GJ, Vervoordeldonk MJ, Tak PP (2010) Role of the cholinergic nervous system in rheumatoid arthritis: aggravation of arthritis in nicotinic acetylcholine receptor alpha7 subunit gene knockout mice. Ann Rheum Dis 69(9):1717–1723

124. Waldburger JM, Boyle DL, Pavlov VA, Tracey KJ, Firestein GS (2008) Acetylcholine regulation of synovioyte cytokine expression by the alpha7 nicotinic receptor. Arthritis Rheum 58(11):3439–3449

125. Buijs RM, van der Vliet J, Huitinga I, Escobar C (2008) Spleen vagal denervation inhibits the production of antibodies to circulating antigens. PLoS One 3(9):e3152

126. Rosas-Ballina M, Ochani M, Parrish WR, Ochani K, Harris YT, Huston JM, Chavan S, Tracey KJ (2008) Splenic nerve is required for cholinergic antiinflammatory pathway control of TNF in endotoxemia. Proc Natl Acad Sci U S A 105(31):11008–11013

127. Koopman FA, Chavan SS, Miljko S, Grazio S, Sokolovic S, Schuurman PR, Mehta AD, Levine YA, Faltsys M, Zitnik R, Tracey KJ, Tak PP (2016) Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proc Natl Acad Sci U S A 113(29):8284–8289

128. Elenkov JI, Wilder RL, Chrousos GP, Vizi ES (2000) The sympathetic nerve—an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52(4):595–638

129. Nance DM, Sanders VM (2007) Autonomic innervation and regulation of the immune system (1987–2007). Brain Behav Immun 21(6):736–745

130. Evrengul H, Dursunoglu D, Cobanvara V, Polat B, Selecti D, Kabukcu S, Kaftan A, Semiz E, Kılıc M (2004) Heart rate variability in patients with rheumatoid arthritis. Rheumatol Int 24(4):198–202

131. Baerwald C, Graefe C, Mulh C, Von Wichert P, Krause A (1992) Beta 2-adrenergic receptors on peripheral blood mononuclear cells in patients with rheumatic diseases. Eur J Clin Invest 22(Suppl 1):42–46

132. Straub RH, Harle P (2005) Sympathetic neurotransmitters in joint inflammation. Rheum Dis Clin N Am 31(1):43–59 viii

133. Heijnen CJ, Rouppe van der Voort C, Wulffraat N, van der Net J, Kuis W, Kavelaars A (1996) Functional alpha 1-adrenergic receptors on leucocytes of patients with polycyclic juvenile rheuma-

toid arthritis. J Neuroimmunol 71(1–2):223–226

134. Bellingler DL, Millar BA, Perez S, Carter J, Wood C, ThyagaRajan S, Molinario C, Lubahn C, Lorton D (2008) Sympathetic modulation of immunity: relevance to disease. Cell Immunol 252(1–2):27–56

135. Steinman RM (2012) Decisions about dendritic cells: past, present, and future. Annu Rev Immunol 30:1–22

136. Somersens S, Bhardwaj N (2001) Tethering and tickling: a new role for the phosphatidylinerse receptor. J Cell Biol 155(4):501–504

137. Steinman RM, Nussenzweig MC (2002) Avoiding horror autoxotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci U S A 99(1):351–358

138. Maldonado RA, van Andrian UH (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 108:111–165

139. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK (2006) Interleukin-10-secretory type 1 regulatory T cells in rodents and humans. Immune Rev 212:26–50

140. Skoberne M, Beignon AS, Larsson M, Bhardwaj N (2005) Apoptotic cells at the crossroads of tolerance and immunity. Curr Top Microbiol Immunol 289:259–292

141. Skoberne M, Somersens S, Almodovar W, Truong T, Petrova K, Henson PM, Bhardwaj N (2006) The apoptotic-cell receptor CR3, but not alphaVbeta5, is a regulator of human dendritic-cell immunostimulation function. Blood 108(3):947–955

142. Petit AR, MacDonald KP, O’Sullivan B, Thomas R (2000) Differentiated dendritic cells expressing nuclear ReilB are predominately located in rheumatoid synovial tissue perivascular mononuclear cell aggregates. Arthritis Rheum 43(4):791–800

143. Martin CA, Carsons SE, Kowalewski R, Bernstein D, Valentino M, Santiago-Schwarz F (2003) Aberrant extracellular and dendritic cell (DC) surface expression of heat shock protein (hsp)70 in the rheumatoid joint: possible mechanisms of hsp70-DC-mediated cross-priming. J Immunol 171(11):5736–5742

144. Lebre MC, Jongsloed SL, Tas SW, Smeets TJJ, McInnes IB, Tak PP (2008) Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. Am J Pathol 172(4):940–950

145. van Lieshout AW, Barrera P, Smeets RL, Pesman GJ, van Kuijk PL, van den Berg WB, Radstake TR (2005) Inhibition of TNF alpha during maturation of dendritic cells results in the development of semi-mature cells: a potential mechanism for the beneficial effects of TNF alpha blockade in rheumatoid arthritis. Ann Rheum Dis 64(3):408–414

146. Balanescu A, Radu E, Nat R, Regalia T, Bojinca V, Ionescu R, Balanescu S, Savu C, Predeteanu D (2005) Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients. Int J Clin Pharmacol Res 25(1):9–18

147. Park JE, Jang J, Choi JH, Kang MS, Woo YJ, Seong YR, Choi JH, Jang J, Choi JH, Kang MS, Woo YJ, Seong YR, Choi

148. Ren Y, Yang Y, Yang J, Xie R, Fan H (2014) Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation
and inhibit collagen-induced arthritis in mice. Int Immunopharmacol 21(1):247–254

149. Zhang L, Fu J, Sheng K, Li Y, Song S, Li P, Song S, Wang Q, Chen J, Yu J, Wei W (2015) Bone marrow CD11b(+)F4/80(+) dendritic cells ameliorate collagen-induced arthritis through modulating the balance between Treg and Th17. Int Immunopharmacol 25(1):96–105

150. Hilkens CM, Isaacs JD (2013) Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin Exp Immunol 172(2):148–157

151. Ahmed MS, Bae YS (2016) Dendritic cell-based immunotherapy for rheumatoid arthritis: from bench to bedside. Immune Netw 16(1):44–51

152. Martin E, O'Sullivan B, Low P, Thomas R (2003) Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 18(1):155–167

153. Bell GM, Anderson AE, Diboll J, Reece R, Etherington O, Harry RA, Fouweather T, MacDonald C, Chadwick T, McColl E, Dunn J, Dickinson AM, Hilkens CM, Isaacs JD (2017) Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis 76(1):227–234

154. Voigtlander C, Rossner S, Cierpka E, Theiner G, Wiethe C, Menges M, Schuler G, Lutz MB (2006) Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J Immunother 29(4):407–415

155. Lim DS, Kang MS, Jeong JA, Bae YS (2009) Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur J Immunol 39(5):1334–1343

156. Ludewig B, Ochsenbein AF, Odermatt B, Paulin D, Hengartner H, Zinkernagel RM (2000) Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 191(5):795–804